Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Program Description

Navigating the complex and rapidly evolving treatment landscape for prostate cancer presents significant challenges for managed care and oncology pharmacists. The disease is characterized by a wide range of prognoses, from indolent to highly aggressive, and is further complicated by significant disparities in diagnoses. From a managed care perspective, balancing the high cost of novel therapies against the need to provide timely access to effective, personalized care may present unique challenges. This session will review the latest therapeutic advancements in prostate cancer, with a focus on optimizing patient care and outcomes. Speakers will discuss the evolving role of second-generation anti-androgens, PARP inhibitors, and the use of molecular testing to personalize therapy. A key focus will be the role of the managed care pharmacist through an examination of the cost-effectiveness of advanced prostate cancer therapies and strategies to ensure equitable access and optimize therapeutic outcomes.

Target Audience: Managed Care Pharmacist, Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Investigate the evolving treatment landscape for prostate cancer, including the role of second-generation anti-androgens, PARP inhibitors, and the use of molecular testing in personalizing therapy to optimize patient outcomes.
2. Examine the latest clinical and safety evidence for new and emerging anti-androgens, PARPi, and PARPi/anti-androgen combinations used to treat prostate cancer.
3. Compare the cost-effectiveness of advanced prostate cancer treatments and strategies to optimize therapeutic access and outcomes in managed care settings.